On August 3, 2011
Dendreon CEO Dumped $1M in Stock Before Withdrawing Revenue Guidance
Dendreon (DNDN) has done it again: the company that makes the $93,000 prostate cancer drug Provenge pulled its investor guidance today after admitting there is no way it can meet its revenues…
No tags for this post.
0 Comments